News related to the Enterprise, its Stakeholders, and HIV Vaccine Research

Enterprise Webinar on Antibody Durability - December 3, 2013

The Enterprise held a webinar to share highlights from the recent thinktank on antibody durability,


Enterprise Webinar on Strategic Directions for Therapeutic Vaccines Research - November 14, 2013

The Enterprise together with AVAC, the Bill & Melinda Gates Foundation and the Treatment Action Group (TAG) hosted a consultation in September on strategic directions for therapeutic vaccines research.  Join us on Monday, 18 November at 12:00 EST for a webinar to share highlights from the consultation. You can register for the webinar here,

AIDS Vaccine 2013 Webcasts and Resources - October 16, 2013

AIDS Vaccine 2013 welcomed more than 900 of the world's leading vaccine researchers, funders and policy makers to Barcelona, Spain for four days of exchange, debate and direction-setting for the field. Check out the conference webcasts, and ePosters,

Experts to Report On Advances in The Search For The Ultimate HIV Prevention Tool – A Vaccine – At AIDS Vaccine 2013 - September 25, 2013

More than 450 research studies outlining the latest advances and obstacles in the search for an AIDS vaccine will be presented and debated at AIDS Vaccine 2013, the world's only scientific meeting dedicated exclusively to HIV vaccine research.

Functional Glycomics in HIV Vaccine Design: Funding Opportunity and Workshop Report - August 1, 2013

The NIH is offering R01 grants to help investigate structural and conformational features of HIV glycosylation that may lead to novel HIV vaccine design approaches; and to elucidate the impact of differential glycosylation on the quality of the immune response to HIV.  The deadline to apply is 02 December,

Latebreaker Abstracts - July 29, 2013

The deadline to submit later breaker abstracts for AIDS Vaccine 2013 is 11 August.  To submit yours, visit

Enterprise and Partners Explore New Timely Topics in HIV Vaccines - July 1, 2013

The Enterprise and partners will focus on identifying synergies between therapeutic and preventive HIV vaccines and exploring strategies to generate long-lasting immune responses from an HIV vaccine

Timely Topics in HIV Vaccines: VISP Meeting Report - June 25, 2013

The Enterprise and partners held a consultation on 14 - 15 March 2013 around the issue of VISP/R.  The full meeting report is available to download below.

A Glimpse at our HIV Vaccine History - June 25, 2013

In a brief history of the global effort to develop a preventive HIV vaccine (Vaccine 2013, in press), Enterprise champion, Jose Esparza has set down the highs and lows of 30 years of research and development on HIV vaccines that have brought us where we are today. This is an important contribution because many senior HIV vaccine scientists have forgotten what we did and why we did it and, conversely, many younger scientists are not aware of those past efforts.

Enterprise Secretariat Report on the 2013 HVTN Full Group Meeting - June 4, 2013

The Enterprise Secretariat attended the 2013 HVTN Full Group meeting in May and developed a report on sessions attended.  Check out the report here.

Syndicate content
Global HIV Vaccine Enterprise, 64 Beaver Street, # 352, New York, NY 10004 | +1 212-461-3692 or toll free at +1-866-966-4483
All Content ©2005 - 2013 Global HIV Vaccine Enterprise   |   Terms of Use   |   Privacy Policy   |   Log In / My Account